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＜研究成果の概要＞ 
本研究では，下記の種々の素材からなるゲル化ポリマーを，ドラッグデリバリーシステム⽤担体，再⽣
医療⽤材料，⻭科充填剤等の医療⽤材料としての応⽤可能性を検討するため，それらの基礎物性評価を
⾏った。 
１）⽣分解性合成⾼分⼦を⽤いた温度応答性ゾルゲル転移ポリマー 
これまでに，脂肪族ポリエステルと PEG からなる共重合体(tri-PCG)が，温度に応答してゾルゲル転移
を⽰し，インジェクタブルポリマー(IP)として利⽤可能であることを報告してきた。さらに，tri-PCG 末端
にアクリル基が結合した tri-PCG-Acryl ミセル溶液と，疎⽔性ポリチオール内包 tri-PCG ミセル溶液を混
合し，温度に応答して共有結合形成により不可逆的ゲル化能を⽰す IP 製剤を開発した。この IP 製剤を，
マウス⽪下に投与したところ体温に応答してゲル化し，60 ⽇以上のゲル状態を維持し，良好な⽣体適合
性を⽰すことを確認した。特に，ペプチド薬剤としてグルカゴン様ペプチド-1(GLP-1)内包ゲルをマウス
に⽪下投与後，⾎中薬剤濃度を 25 ⽇以上薬理活性有効濃度以上に維持できることを明らかにした。 
２）DNA 合成⾼分⼦ハイブリッドを⽤いたゾルゲル転移ポリマー 
 PEG 両末端にグアニンを結合したマクロモノマー（dG4-PEG-dG4）が⽣体内 Na+イオン濃度下で 4 重鎖
を形成してゲル化することを確認した。これに相補鎖を加えて 4 重鎖を解離させてゲルを選択的に溶解
可能であることや，切断したゲルを接触させると⾃⼰修復機能を発現することも明らかとなった。また，
ヘミン添加によりペルオキシダーゼ活性を発現するゲルビーズを調製することも可能であった。さらに，
同様の⼿法で，酸性 pH 領域で i-motif という特殊な 4 重鎖を形成するマクロモノマーdC5-PEG-dC5 につい
ても合成し，これが pH 応答性のヒドロゲルを形成することを⾒出した。 
３）多糖類を⽤いたポリイオンコンプレックス形成によるゾルゲル転移ポリマー 
 アニオン性多糖としてアルギン酸，カチオン性多糖としてキトサンを使⽤し，ポリイオンコンプレッ
クス（PIC）形成を利⽤して，各多糖・オリゴ糖の溶液の混合によりゲル化させる⼆液混合法についてゲ
ル化条件やゲル強度等を検討した。さらに多糖／オリゴ糖による PIC ゲル強度向上の⽬的でアルギン酸
／キトサンによる多糖同⼠の PIC ゲル形成についても検討を⾏った結果，キトサンの塩基性溶液を⽤い
ることによりアルギン酸／キトサン混合均⼀溶液を経てゲル化させる条件を⾒いだした。 
 
＜各論⽂の概要＞ 
Peptide drug release behavior from biodegradable temperature-responsive injectable hydrogels exhibiting 
irreversible gelation. K. Takata, A. Kuzuya, Y. Ohya 他 5 名, Gels., 3(4), 38 (2017) ; doi: 10.3390/gels3040038. 
 ⽣分解性インジェクタブルポリマー(IP)ヒドロゲルからのグルカゴン様ペプチド 1(GLP-1)の放出挙動
を調査した。このヒドロゲルは、チオール-エン反応による共有結合形成により、温度応答性の不可逆的
なゲル化を⽰す。不可逆的 IP 製剤を使⽤した場合には，可逆的（物理ゲル化）IP 製剤と⽐べて持続性の
⾼い GLP-1 の in vitro 放出が観察された。さらに、ラットへの不可逆的 IP 製剤を⽪下注射後、⾎中の GLP-
1 濃度を薬理活性レベルに維持できることが⽰された。開発した IP システムは、ペプチド薬物や他の⽔
溶性⽣物活性試薬の低侵襲持続薬物放出型ドラッグデリバリーシステムへの応⽤が期待できる。 
 
Bulk pH-Responsive DNA Quadruplex Hydrogels Prepared by Liquid-Phase, Large-Scale DNA Synthesis. S. Tanaka, 
Y. Ohya, A. Kuzuya 他 3 名, ACS Macro Lett., 7, 295-299 (2018).  
 ⽣体適合性に富むオリゴデオキシヌクレオチド（ODN）とポリエチレングリコール（PEG）のみから構
成される新しい pH 応答性ヒドロゲルを調製した。液相 DNA 合成技術を使⽤して、従来のシステムの
1000 倍のスケールで、5 つのデオキシシチジン残基を線形または 4 分岐型の PEG の末端に結合し、得ら
れた結合体をマクロモノマーとしてヒドロゲルを調製した。結合体の合成は、⼀般的なホスロアミダイ
ト法を使⽤して、PEG を半固相基質として ODN を伸⻑することによって⾏った。得られた dC5-PEG コ
ンジュゲートは、特殊な DNA 四重鎖である i-motif の形成により、⾮常に安定した⾼弾性率のヒドロゲ
ルを形成した。 2 つの線状結合体の間にわずか 1 つの化学結合を導⼊すると、i-motif の熱安定性が著し
く向上し，融解温度の向上が認められた。元の線状結合体のみからなる場合と⽐較して、⾮線形的にがレ
オロジー特性が向上することも観察された。これは、マクロモノマー間の結合により⽣じた位相的絡み
合いによるものであると考えられる。 
 
Preparation of polyelectrolyte complex gel of sodium alginate with chitosan using basic solution of chitosan. D. 
Komoto, T. Furuike, H. Tamura, Int. J. Biol. Macromol., 126, 54-59 (2019). 
 ⼀般に、キトサン(CS)は塩基性溶液に溶解しないが、炭酸⽔素ナトリウムを使⽤すると塩基性 CS 溶液
が調製できることを⾒出した。CS は塩基性条件（pH 8 付近）でカルバメートイオンに変換され、この媒
質中でアニオン性として挙動することが，NMR 測定により明らかになった。この知⾒に基づき、塩基性
CS 溶液と D-グルコノラクトン（GDL）を使⽤して，アルギン酸ナトリウム（SA）と CS からなる新規な
ポリイオンコンプレックスゲルを調製することに成功した。この系のゲル形成メカニズムを、1H および
13C NMR 測定結果に基づいて考察した。また，SA/CS ポリイオンコンプレックスゲルは，均質なゲルで
あり，弾性率は SA/キトサンオリゴマーゲルよりも⾼く，その最⼤値は 7000 Pa を超えることが分かった。
この新しいポリイオンコンプレックスゲルは、組織⼯学、薬物送達システム、燃料電池などへの応⽤が期
待できる。 
 
DNA quadruplex hydrogels beads showing peroxidase activity. 
S. Tanaka, Y. Ohya, A. Kuzuya 他 2 名, J. Electrochem. Soc.,166(9), B3271-B3273 (2019),  
 ⽣分解性でインテリジェント性と⾃⼰修復性を有する DNA 四重鎖ヒドロゲルビーズにヘミンを加え
ることにより，ペルオキシダーゼ活性を⽰すヒドロゲルビーズが調製された。このヒドロゲルビーズは、
dG4-PEG-dG4 トリブロックコポリマーの dG4（デオキシグアノシン 4 量体）部分間の四重鎖形成により形
成されている。ヒドロゲル中の平⾏ G-四重鎖（G-カルテット）へのヘミンの効率的な結合が、ヘミン吸
収の淡⾊効果を測定することにより確認された。ヘミンのペルオキシダーゼ酵素様活性が、蛍光基質と
発⾊基質の使⽤により可視化できた。これらの観察結果は、DNA 四重鎖ヒドロゲルにおける G-カルテッ
トの存在の最初の直接的な証拠と⾔える。 
 
＜謝辞＞ 
本研究の⼀部は 2016-2017 年度関⻄⼤学研究拠点形成⽀援経費において，研究課題「ゾル−ゲル転移を⽰
す⽣体適合ポリマー材料の開発と応⽤」として研究費を受け，その成果を公表するものである。 
 
研究代表者 化学⽣命⼯学部 教授 ⼤⽮裕⼀ 
研究分担者 化学⽣命⼯学部 教授 ⽥村 裕 
  化学⽣命⼯学部 教授 古池哲也 
  化学⽣命⼯学部 教授 葛⾕明紀 
 gels
Article
Peptide Drug Release Behavior from Biodegradable
Temperature-Responsive Injectable Hydrogels
Exhibiting Irreversible Gelation
Kazuyuki Takata 1, Hiroki Takai 1, Yuta Yoshizaki 2, Takuya Nagata 1, Keisuke Kawahara 1,
Yasuyuki Yoshida 1,3, Akinori Kuzuya 1,2 ID and Yuichi Ohya 1,2,* ID
1 Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering,
3-3-35 Yamate, Suita, Osaka 564-8680, Japan; kazuyuki.takata@shionogi.co.jp (K.T.);
k266872@kansai-u.ac.jp (H.T.); k161109@kansai-u.ac.jp (T.N.); kawaharakeisuke43@gmail.com (K.K.);
k831414@gmail.com (Y.Y.); kuzuya@kansai-u.ac.jp (A.K.)
2 Organization for Research and Development of Innovative Science and Technology (ORDIST),
Kansai University, Suita, Osaka 564-8680, Japan; y-yoshi@kansai-u.ac.jp
3 Research Fellow of Japan Society for the promotion of Science, Kojimachi, Chiyoda-ku,
Tokyo 102-0083, Japan
* Correspondence: yohya@kansai-u.ac.jp; Tel.: +81-6-6368-1121
Received: 4 October 2017; Accepted: 13 October 2017; Published: 15 October 2017
Abstract: We investigated the release behavior of glucagon-like peptide-1 (GLP-1) from a biodegradable
injectable polymer (IP) hydrogel. This hydrogel shows temperature-responsive irreversible gelation due
to the covalent bond formation through a thiol-ene reaction. In vitro sustained release of GLP-1 from
an irreversible IP formulation (F(P1/D+PA40)) was observed compared with a reversible (physical
gelation) IP formulation (F(P1)). Moreover, pharmaceutically active levels of GLP-1 were maintained
in blood after subcutaneous injection of the irreversible IP formulation into rats. This system should
be useful for the minimally invasive sustained drug release of peptide drugs and other water-soluble
bioactive reagents.
Keywords: injectable polymers; sustained release; sol-to-gel transition; hydrogel; peptide
drug delivery
1. Introduction
Various temperature-responsive water-soluble polymers have been investigated for application in
drug delivery systems (DDSs) [1–9]. Of these, several polymers in aqueous solution exhibit a temperature-
responsive sol-to-gel transition between room temperature (r.t.) and body temperature and can thus be
used as injectable polymer (IP) systems. Such polymer solutions can be mixed with water-soluble bioactive
reagents such as proteins, peptides, or living cells before injection, and form a hydrogel entrapping these
reagents at the injection site in the body. If the polymer can be hydrolyzed to low-molecular-weight
compounds that can be metabolized or excreted from the body, such biodegradable IP systems could
potentially act as implantable minimally invasive sustained drug release systems [10–12].
There have been many reports on drug release from hydrogels. The release rates of drugs from
hydrogels are influenced by several factors, such as the hydrophilicity/hydrophobicity (solubility)
and molecular weight of the drug, the degradation rates of the hydrogel, the mesh size of the network,
and the diffusion constant of the drug in the hydrogel [13]. In general, temperature-responsive
biodegradable IP hydrogels, once formed in the body, are likely to quickly revert to the sol state
(typically in less than 24 h) at the injection site, where there is a large amount of body fluid [14].
This is because the gelation of such an IP system is caused by non-covalent (hydrophobic) interactions,
and gel formation is an equilibrium process affected by local conditions such as concentration, pH,
Gels 2017, 3, 38; doi:10.3390/gels3040038 www.mdpi.com/journal/gels
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and temperature. This phenomenon may cause rapid disappearance of the hydrogel and more rapid
release of bioactive agents than intended.
To address this problem, we recently reported the generation of biodegradable
temperature-triggered covalent gelation systems exhibiting longer and controllable durations
of the gel state by using a “mixing strategy” [14–16]. We synthesized a tri-block copolymer of
poly(caprolactone-co-glycolic acid) (PCGA), poly(ethylene glycol) (PEG), PCGA-b-PEG-b-PCGA
(tri-PCG), and tri-PCG with acryloyl groups attached at both termini (tri-PCG-Acryl)
(Figure 1). A mixture of tri-PCG-Acryl micelle solution and tri-PCG micelle solution containing
dipentaerythritolhexakis(3-mercaptopropionate) (DPMP) (Figure 1) as a hydrophobic hexa-functional
polythiol exhibited an irreversible sol-to-gel transition by covalent cross-linking using a bio-orthogonal
Michael-addition-type thiol-ene reaction in response to a temperature increase [15,16]. The mixed
micelle solution remained in the sol state just after mixing at r.t., but underwent gelation in response to
a temperature increase. Once formed, the hydrogel stayed in the gel state even after cooling. In this
system, the acryloyl groups at the copolymer termini and the thiol groups of DPMP existed separately
in different micelles just after mixing. Covalent bond formation between the acryloyl and thiol groups
occurred only upon sol-to-gel transition induced by a temperature increase, since this temperature
rise induced inter-micellar aggregation due to hydrophobic interactions, resulting in a physically
cross-linked hydrogel. During the aggregation process, the micelle cores fused and subsequently the
thiol groups of DPMP in the tri-PCG micelle core covalently cross-linked with the acryloyl groups
via the Michael-addition-type thiol-ene reaction. This system existed for a longer and controllable
duration time in the gel state. The duration time of the gel state after subcutaneous injection in vivo
could be altered easily from 1 day to more than 60 days simply by changing the mixing ratio of
DPMP/tri-PCG and tri-PCG-Acryl [15].
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tolerability, and availability. However, peptides must be administered via the parenteral route 
because their half-life in the body is extremely short and their oral absorption is poor. Consequently, 
when continuous exposure to the peptide drug is needed, continuous infusion or multiple injections 
are required to achieve therapeutic efficacy, which is inconvenient and distressing for patients. Thus, 
there is need to develop sustained release parenteral formulations, where a single injection allows 
the drug to be released over a period of weeks, months, or even years [17,18]. 
As described above, we previously developed a biodegradable temperature-triggered IP system 
exhibiting covalent gelation using a bio-orthogonal reaction and controllable duration times of the 
gel state. This system should have potential utility as a drug deposition method allowing the 
sustained release of peptide drugs. As far as we were aware, there has been no report on the drug 
release behavior using temperature-triggered covalent gelation system. In this study, we evaluated 
this IP system as a sustained peptide drug release device by studying the release behavior of a peptide 
from hydrogels prepared using our IP system. We chose glucagon-like peptide-1 (7-36 amide) (GLP-
1) as the peptide model drug. GLP-1 holds promise for the treatment of type 2 diabetes but must be 
continuously infused or administered by multiple injections because of its extremely short half-life 
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Peptides are becoming increasingly important as drugs due to their activity, target specificity,
tolerability, and availability. However, peptides must be administered via the parenteral route
because their half-life in the body is extremely short and their oral absorption is poor. Consequently,
when continuous exposure to the peptide drug is needed, continuous infusion or multiple injections
are required to achieve therapeutic efficacy, which is inconvenient and distressing for patients. Thus,
there is need to develop sustained release parenteral formulations, where a single injection allows the
drug to be released over a period of weeks, months, or even years [17,18].
As described above, we previously developed a biodegradable temperature-triggered IP system
exhibiting covalent gelation using a bio-orthogonal reaction and controllable duration times of the gel
state. This system should have potential utility as a drug deposition method allowing the sustained
release of peptide drugs. As far as we were aware, there has been no report on the drug release behavior
using temperature-triggered covalent gelation system. In this study, we evaluated this IP system as
a sustained peptide drug release device by studying the release behavior of a peptide from hydrogels
prepared using our IP system. We chose glucagon-like peptide-1 (7-36 amide) (GLP-1) as the peptide
model drug. GLP-1 holds promise for the treatment of type 2 diabetes but must be continuously
Gels 2017, 3, 38 3 of 11
infused or administered by multiple injections because of its extremely short half-life [19–21]. This is
the first report on the drug release behavior using biodegradable temperature-responsive covalent
gelation system exhibiting long-term release of peptide drugs.
2. Results and Discussion
Tri-PCGs (tri-PCG-1 and tri-PCG-2) and tri-PCG-Acryl were successfully synthesized according to
the methods reported previously [15] (Schemes S1 and S2). Several characteristics of the polymers are
shown in Supplementary Materials (Tables S1 and S2). The IP formulations were typically prepared by
mixing DPMP-loaded tri-PCG micelles in phosphate buffered saline (PBS) (Solution A) and tri-PCG-Acryl
micelles in PBS (Solution B) at a mixing ratio A/B = 3/2, with the weight content of tri-PCG-Acryl in
the total polymer being 40%. This IP formulation is denoted as F(P1/D+PA40), where P1, /D, and +PA40
denote the presence of tri-PCG-1 added, the presence of DPMP added, and the amount tri-PCG-Acryl
added was 40 wt % in total polymers, respectively. The control formulation, prepared using only tri-PCG-1
or tri-PCG-Acryl, is denoted as F(P1) or F(PA). The phase diagrams for tri-PCG-1 and tri-PCG-Acryl are
shown in Supplementary Materials (Figure S1). Both these polymer solutions (25 wt %) and their mixtures
adopted a gel state at 37 ◦C.
The sol-to-gel transition behavior of the F(P1/D+PA40) and F(P1) formulations containing GLP-1
are shown in Figure 2. Both formulations showed a sol-to-gel transition in response to a temperature
increase from 25 to 37 ◦C. The presence of GLP-1 had almost no effects on the sol-to-gel transitions
of these formulations (Figure S2), and the transition temperatures were between 25 and 37 ◦C.
After cooling to 4 ◦C, F(P1) containing GLP-1 adopted the sol state, showing that the sol-to-gel
transition was reversible. In contrast, F(P1/D+PA40) containing GLP-1 remained in the gel state after
cooling, showing that the sol-to-gel transition was irreversible. These behaviors are in accordance with
our earlier observations in the absence of GLP-1 [15]. Consequently, the presence of GLP-1 had no
effect on the phase transition irreversibility of the formulation.
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Figure 2. Photographs of (a) F(P1) hydrogel containing GLP-1 and (b) F(P1/D+PA40) hydrogel
containing GLP-1 after heating at 37 ◦C for 1 min and subsequent cooling at 4 ◦C for 1 min.
We next investigated the in vitro release behavior of GLP-1 from the formulations. Figure 3 shows
the cumulative amount of GLP-1 released from F(P1/D+PA40) and F(P1) hydrogels at 37 ◦C in vitro.
Both hydrogels showed rapid release of GLP-1 during the first two days, and the release rate from F(P1)
was higher than that from F(P1/D+PA40). On Day 2, the cumulative amount of GLP-1 released from
F(P1) and F(P1/D+PA40) was about 59% and 38%, respectively. We previously reported that irreversible
F(P1/D+PAx) IP hydrogels with higher DPMP and tri-PCG-Acryl content showed a lower swelling
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ratio compared with hydrogel without cross-linking (F(P1)) and compared with hydrogels with lower
DPMP and tri-PCG-Acryl content. This lower swelling was due to the higher cross-linking densities
of these gels [15]. The mesh size of a hydrogel increases due to swelling and cross-linking density
correlates with the swelling ratio [22]. The main reason for the more rapid release of GLP-1 from F(P1)
compared to F(P1/D+PA40) hydrogel is likely due to differences in the swelling ratios and diffusion
coefficients of the two gels. Figure 4 shows photographs of the hydrogels taken during the release
tests. The F(P1) hydrogel adopts a highly swollen state within 2 h and the formulation is essentially
a sol after Day 1. By Day 2, the release of GLP-1 from F(P1) becomes gradual. As shown in Figure 4,
although F(P1) reverts to the sol state completely by Day 30, 100% cumulative release is not attained.
The GLP-1 molecule can adsorb onto the polymer chains by hydrophobic interactions [23], and GLP-1
may be unstable due to spontaneous hydrolysis; consequently, 100% of the GLP-1 molecules could
not be detected by reversed-phase high-performance liquid chromatography (RP-HPLC) analysis.
On the other hand, the release of GLP-1 from the F(P1/D+PA40) hydrogel became very slow after Day 2.
As shown in Figure 4, F(P1/D+PA40) remained in the gel state even after 30 days. The storage modulus
(G’) (4202 Pa) of F(P1/D+PA40) was larger than the loss modulus (G”) (326 Pa) and was similar to that
of the sample on Day 0 (4696 Pa) (Table 1). As described above for F(P1) above, not all the GLP-1
molecules could be detected by RP-HPLC analysis. Regardless, some GLP-1 remained inside the
hydrogel and was released very slowly.
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Table 1. Physical properties of the hydrogels during release tests and in vivo experiments.
Formulation In Vitro or Vivo Day G‘ (Pa) G” (Pa)
F(P1) in vitro
0 353 99
30 N.D. 1 N.D. 1
in vivo 25 N.D. 2 N.D. 2
F(P1/D+PA40)
in vitro
0 4694 569
30 4202 326
in vivo 25 1147 364
1 not detected because of being dissolved, 2 not detected because of disappearance.
To evaluate the cytocompatibilities of the IP formulations, we investigated the cytotoxicity of each
formulation and their components towards L929 mouse fibroblast cells. The experiments were under
dilute conditions (<1 wt %), below the critical gelation concentration of each polymer. The results are
shown in Figure 5. F(P1) (tri-PCG solution) exhibited no cytotoxicity over the concentration range
tested. In contrast, F(P1/D) (tri-PCG micelle entrapping DPMP: solution (A) and F(PA) (tri-PCG-Acryl
micelle solution: Solution (B) showed weak cytotoxicity at concentrations above 0.01 wt % and
0.1 wt %, respectively. Liu et al. reported that oligo-thiols such as dithiothreitol (DTT) are cytotoxic
towards NIH/3T3 fibroblasts and rat bone marrow mesenchymal stem cells (BMSCs) [24]. Klouda et al.
reported that polymers with multivalent acryloyl groups showed cytotoxicity [25]. Our results are
therefore in agreement with these earlier reports. The thiol groups of DPMP in F(P1/D) and the acryloyl
groups in F(PA) exhibited cytotoxicity, probably because of their interaction with the cell membrane.
In contrast, the cytotoxicity of F(P1/D+PA50) was negligible, similar to that of F(P1). These results
suggest that the thiol groups of DPMP and the acryloyl groups of tri-PCG-Acryl reacted with each
other, decreasing the number of both functional groups, and that the reaction products exhibited no
cytotoxicity. Consequently, F(P1/D+PA50) showed no significant cytotoxicity.
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GLP-1 is not detectable by this system. GPL-1 disappeared from the plasma very quickly following the
injection of the GLP-1 solution: some GLP-1 was detected in the plasma after 2 h, but essentially none
was detected after 1 day. This is as expected because the half-life of GLP-1 after subcutaneous injection
is very short (t1/2 = 9 min) [21]. The injection of F(P1) formulations resulted in much higher plasma
GLP-1 levels compared to the GLP-1 solution at 2 h, suggesting that the F(P1) hydrogel provided
a delayed effect compared to the solution, allowing GLP-1 to be absorbed from the injection site
and transferred to the blood circulation. The plasma GLP-1 level subsequently decreased rapidly,
to 100 ng/L after 19 days, which is slightly higher than the level found in the control rats. The plasma
GLP-1 level decreased to the control level 25 days after the injection of F(P1) hydrogel. These results
are in relatively good agreement with the in vitro release tests (Figure 3): rapid, early release of GLP-1
from F(P1) hydrogel, then continuous sustained release from the sol state polymer chains acting
as adsorbents in the subcutaneous space. F(P1/D+PA40) hydrogel also provided a relatively high
plasma GLP-1 level 2 h after injection, similar to that of the GLP-1 solution and much lower than
that of the F(P1) hydrogel. This result suggests that the initial burst release of GLP-1 was suppressed
by the lower swelling of the gel resulting from covalent cross-linking, in good agreement with the
in vitro results. Interestingly, although F(P1/D+PA40) hydrogel exhibited no detectable release of
GLP-1 after three days in vitro, rats in the F(P1/D+PA40) group showed higher plasma GLP-1 levels
(about 300 ng/L) between Day 7 and Day 25 compared with the F(P1) and control rats. These results
suggest that the hydrogel network in F(P1/D+PA40) might be partially hydrolyzed by body fluids
or by autocatalytic effects [26], resulting in the slow release of the GLP-1 entrapped in the hydrogel
matrix in vivo. This speculation is supported by the results of a physical strength study (Table 1).
The G’ value of subcutaneously implanted F(P1/D+PA40) hydrogel was 1147 Pa after 25 days, which is
much lower than the G’ value obtained in vitro after 30 days’ incubation (4202 Pa), suggesting partial
degradation. Kim et al. reported that the blood glucose level decreased significantly at a plasma GLP-1
level of around 200 ng/L [27]. Therefore, the plasma GLP-1 level (about 300 ng/L) obtained following
the injection of F(P1/D+PA40) hydrogel containing GLP-1 should be sufficient to be pharmacologically
active over a period of 25 days. Figure 7 shows photographs of the sites where the formulations were
injected subcutaneously in rats 25 days earlier. All F(P1) hydrogel injected disappeared within 25 days,
whereas all F(P1/D+PA40) hydrogel remained at the injection site after 25 days and was in the gel state
(G’ (1147 Pa) was larger than G” (364 Pa); (Table 1)). We can, therefore, expect the continuous release of
GLP-1 from F(P1/D+PA40) hydrogel even after 25 days.
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3. Conclusions 
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4. Materials and Methods  
4.1. Materials 
Tri-PCG-1 and tri-PCG-2 were synthesized by the ring-opening polymerization of  
ε-caprolactone (CL) glycolide (GL) in the presence of PEG (molecular weight (MW) = 1500 Da) 
according to the methods reported previously (Scheme S1) [15]. The Mn of PCGA segments, the total 
Mn, and the molar ratio of glycolic acid (GA) units to CL units in the tri-PCG-1 copolymer (CL/GA) 
were 1950, 5400 Da, and 3.4, respectively, and for tri-PCG-2 the values were 1250, 4000 Da, and 3.9, 
respectively (Table S1). Tri-PCG-Acryl was synthesized from tri-PCG-2 by the method described 
previously [15]. The total Mn and the degree of substitution by acryloyl groups were 4200 Da and 
91%, respectively (Table S2). GLP-1 (7–36 amide) was purchased from Aviva Systems Biology, Corp. 
(San Diego, CA, USA). DPMP was a gift from SC Organic Chemical Co., Ltd. (Osaka, Japan). Fetal 
calf serum (FCS) was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Eagle’s minimum 
essential medium (E-MEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Mouse 
fibroblast NCTC clone 929 (L929) cells were obtained from the Health Science Research Resources 
Bank (HSRRB, Osaka, Japan). Spague-Dawley (SD) rats (7 weeks old, female, 180 g average body 
weight) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Water was purified using a Milli-
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e ac ie e lo g-ter aintenance levels of plasma GLP-1 in vi o by using a biodegradable IP
system that shows irreversible gelation due to covalent bond formation. Co pared with a conventional
physical gelation system, this irreversible hydrogel system exhibits a lower swelling ratio early in the
drug release process, a suppressed initial burst, and sustained release of the encapsulate drug. Moreover,
the system remained in the gel state for a longer time and gradually degraded after subcutaneous injection,
which could help maintain a therapeutic blood drug level for over 1 month. This IP form lation did
not exhibit severe cytotoxicity. Therefore, this irreversible IP hydrogel system holds promise for use in
a minimally invasive sustained drug release system for hydrophilic compounds such as peptides and
proteins. Especially, the IP system with GLP-1 can be a new effective therapeutic system for type 2 diabetes
providing good quality of life of patients without frequent injections.
4. Materials and Methods
4.1. Materials
Tri-PCG-1 and tri-PCG-2 were synthesized by the ring-opening polymerization of ε-caprolactone
(CL) glycolide (GL) in the presence of PEG (molecular weight (MW) = 1500 Da) according to the
methods reported previously (Scheme S1) [15]. The Mn of PCGA segments, the total Mn, and the
molar ratio of glycolic acid (GA) units to CL units in the tri-PCG-1 copolymer (CL/GA) were 1950,
5400 Da, and 3.4, respectively, and for tri-PCG-2 the values were 1250, 4000 Da, and 3.9, respectively
(Table S1). Tri-PCG-Acryl was synthesized from tri-PCG-2 by the method described previously [15].
The total Mn and the degree of substitution by acryloyl groups were 4200 Da and 91%, respectively
(Table S2). GLP-1 (7–36 amide) was purchased from Aviva Systems Biology, Corp. (San Diego, CA,
USA). DPMP was a gift from SC Organic Chemical Co., Ltd. (Osaka, Japan). Fetal calf serum (FCS)
was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Eagle’s minimum essential medium
(E-MEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Mouse fibroblast NCTC
clone 929 (L929) cells were obtained from the Health Science Research Resources Bank (HSRRB, Osaka,
Japan). Spague-Dawley (SD) rats (7 weeks old, female, 180 g average body weight) were purchased
from Japan SLC, Inc. (Hamamatsu, Japan). Water was purified using a Milli-Q (Merck Millipore,
Billerica, MA, USA) system. All other reagents and organic solvents were of commercial grade and
were used without further purification.
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4.2. Preparation of the IP Formulations
The IP formulations were prepared as reported previously [15]. DPMP-loaded tri-PCG micelle
solution (Solution A) was prepared as follows. Tri-PCG and DPMP were placed in a glass vial and
dissolved with a small amount of acetone at r.t. The solution was dropped into pure water in a flask
stirred at r.t. for 10 min, and then evaporated to remove the acetone. The aqueous solution was
lyophilized to obtain powdery DPMP-loaded tri-PCG micelles. The powder was placed in a glass vial
and a predetermined amount of PBS was added. After mixing with a vortex mixer for 1 min at r.t.,
the obtained suspension was heated to 65 ◦C and kept at 65 ◦C for 1 min, then mixed using a vortex
mixer for 1 min at r.t. The glass vial was immersed in ice-cold water for 2 min and mixed with a vortex
mixer for 1 min at r.t. These procedures were repeated until no insoluble particles were observed to
give DPMP-loaded tri-PCG micelle solution (Solution A).
Tri-PCG-Acryl micelle solution (Solution B) was prepared as follows. Tri-PCG-Acryl was placed
in a glass vial and PBS was added. After mixing with a vortex mixer for 1 min at r.t., the obtained
suspension was heated to 65 ◦C and kept at 65 ◦C for 10 s, then further mixed using a vortex mixer for
1 min at r.t. The glass vial was immersed in ice-cold water for 2 min and mixed with a vortex mixer
for 1 min at r.t. These procedures were repeated until no insoluble particles were observed to give
tri-PCG-Acryl micelle solution (Solution B).
Finally, Solution A and Solution B were mixed at desired ratios to give IP formulations. The IP
formulations are expressed as F(P1/D+PAx), where P1, /D, and +PAx denote the presence of tri-PCG-1
added, the presence of DPMP added, and the amount of tri-PCG-Acryl added was x wt % in
total polymers.
4.3. In Vitro Release Test of GLP-1
IP formulations F(P1/D+PA40) containing GLP-1 were prepared as follows. A predetermined amount
of GLP-1 was dissolved in Solution A (total polymer concentration = 26 wt %) by mixing and sonication,
and the solution was then mixed with Solution B (total polymer concentration = 26 wt %). The pH
was adjusted to 7.4 with 1N NaOH aqueous solution or HCl aqueous solution, and the total polymer
concentration was adjusted to 25 wt % by the addition of PBS. The mixing ratio of solution A/solution B
was 3/2, with the content of tri-PCG-Acryl in the total polymer being 40 wt %, F(P1/D+PA40). As a control,
IP formulation containing only tri-PCG-1 (without DPMP or tri-PCG-Acryl) and GLP-1 F(P1) was
prepared by a similar method using only Solution A. The GLP-1 concentration in each IP formulation was
7.5 mg/mL.
Each formulation (200 µL) was placed in a glass vial and incubated at 37 ◦C for 30 min to
obtain a hydrogel, then 1 mL of PBS as a release medium was gently added. At each sampling
time, 0.6 mL of supernatant was removed and measured, and 0.6 mL fresh PBS was added to the
vial, and the sample was then further incubated at 37 ◦C. The amount of GLP-1 in the sample
solution was determined using a reversed-phase high-performance liquid chromatography (RP-HPLC)
system (Waters, Milford, MA, USA) (column: Vydac 218TP54 (4.6 mm × 250 mm), eluent: acetonitrile
containing 0.1% trifluoroacetic acid (TFA)/water containing 0.1% TFA, 1/4 to 4/1 linear gradient for
25 min; flow rate: 0.8 mL/min; detector: UV at 210 nm).
4.4. Cytotoxicity
The viability of L929 mouse fibroblast cells after incubation with each sample for 24 h was
investigated using a WST-8 assay (Dojindo, Tokyo, Japan). L929 mouse fibroblast cells (100 µL,
2.5 × 103 cells/well) in E-MEM containing 10% fetal bovine serum (FBS) were seeded in a 96-well
microplate and cultured in a humidified atmosphere containing 5% CO2 at 37 ◦C. After preincubation
for 24 h, all the medium supernatant was removed and added to 90 µL of fresh medium. Then, 10 µL
of medium containing an IP formulation was added to each well and further incubated for 21 h.
The medium supernatant was removed again from the wells, and the cells in the wells were washed
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with PBS twice. Thereafter, 90 µL of fresh medium and WST-8 reagent (10 µL) were added to the
wells, and incubation was continued for a further 3 h. The microplates were read at 450 nm using
a microplate reader. The average background absorbance from the control wells was subtracted from
the sample data. The values for each sample were in the linear region of the standard curve for the
WST-8 assay. Data are expressed as the means and SD (n = 6). Cell viability was calculated using the
following equation:
Cell viability (%) = Nt/Nc × 100
where Nt and Nc are the number of cells with or without IP formulation after 21 h of
incubation, respectively.
4.5. In Vivo Experiments
The F(P1/D+PA40) formulation (500 µL) containing GLP-1 was administrated by syringe with
a 25 G needle subcutaneously in the back neck of a rat after anesthetizing with isoflurane. F(P1)
containing GLP-1, F(P1/D+PA40) without GLP-1, and GLP-1 in PBS (pH 7.4) were used as controls.
The volume of all samples was 500 µL, and the concentration of GLP-1 was 7.5 mg/mL.
At each sampling time (2 h–25 days), 250 µL blood samples were obtained from the tail vein
using a blood collection tube (BD Microtainer with K2EDTA, Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). The blood samples were treated with 5 µL of dipeptidyl peptidase IV
inhibitor (Merck Millipore, Billerica, MA, USA) and centrifuged (9100 g, 10 min, 4 ◦C) to obtain
the plasma. The amount of active GLP-1 in the plasma was determined using an ELISA kit
(GLP-1 active form assay kit, Immuno-Biological Laboratories Co., Ltd., Shizuoka, Japan). The results
were expressed as mean ± SE (n = 3–6). Statistical comparisons were made using a Student’s t-test.
A value of p < 0.05 was considered significant. Photographs of the rats injected with F(P1) without
GLP-1 (top) and F(P1/D+PA 40) without GLP-1 just after injection, and after 1 day were shown in
Figure S3 for references. These experiments followed the guidelines for animal experiments at Kansai
University. The experiment was approved by the Ethical Committee for Animal Experiments of Faculty
of Chemistry, Materials and Bioengineering, Kansai University (17 April, 2017, Identification number
1709).
4.6. Rheological Measurements
The physical properties of the formulations after soaking in PBS (release test) or after subcutaneous
injection into rats were investigated at 37 ◦C by rheological measurements using a dynamic rheometer
(Thermo HAAKE RS600, Thermo Fisher Scientific, Waltham, MA, USA). A solvent trap was used to
prevent solvent vaporization. The diameter of the parallel plate was 35 mm, and the gap was 0.2 mm.
The controlled stress and frequency were 0.4 Pa and 1.0 rad/s, respectively.
Supplementary Materials: The following are available online at www.mdpi.com/2310-2861/3/4/38/s1. Table S1:
Characterization of PCGA-b-PEG-b-PCGA triblock copolymers (tri-PCGs); Table S2: Characterization of
tri-PCG-Acryl; Scheme S1: Synthesis of PCGA-b-PEG-b-PCGA triblock copolymer (tri-PCG); Scheme S2: Synthesis
of tri-PCG-Acryl; Figure S1: Phase diagrams of (a) tri-PCG and (b) tri-PCG-Acryl. •: sol; •: gel; •: sol (syneresis).
The gelation temperature (Tgel) of each concentration is indicated; Figure S2: Comparison of the gelation
temperature in the presence or absence of GLP-1 for (a) tri-PCG and (b) tri-PCG-Acryl. •: sol; •: gel; •: sol
(syneresis). The polymer concentration = 25 wt%. The gelation temperature (Tgel) of each sample is indicated;
Figure S3: Photographs of the rats injected with F(P1) without GLP-1 (top) and F(P1/D+PA 40) without GLP-1
just after injection, and after 1 day.
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